Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
8/21/25 NicOx (COX) NCX 470 for Glaucoma / Ocular Hypertension (Ophthalmology) Subscribers Only Subscribers Only Subscribers Only
8/19/25 Viking Therapeutics (VKTX) VK2735 for Obesity Subscribers Only Subscribers Only Subscribers Only
8/18/25 Reunion RE104 for Postpartum Depression (PPD) Subscribers Only Subscribers Only Subscribers Only
8/18/25 Aptose (APTO) tuspetinib for Acute Myelogenous Leukemia (AML) Subscribers Only Subscribers Only Subscribers Only
8/15/25 Pfizer (PFE) Inclacumab for Sickle Cell Disease Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
04/30/2025 Subscribers Only Subscribers Only Trial Announcement - Trial Completion (Emerging Markets)
05/18/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
05/19/2025 Subscribers Only Subscribers Only Trial Data - Updated Results